Skip to content

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

An Open Label Study Evaluating The Effect Of Single Doses Of Pf-04308515 And Prednisone On Carbohydrate Metabolism Utilizing An Oral Glucose Tolerance Test In Healthy Adult Subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01199029
Enrollment
18
Registered
2010-09-10
Start date
2010-08-31
Completion date
2010-09-30
Last updated
2010-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Healthy People, Glucocorticoids, Prednisone

Brief summary

This study will investigate the effect of a single dose of PF-04308515 or prednisone on calculated measures of glucose tolerance and insulin resistance by using a modified oral glucose tolerance test.

Interventions

10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)

DRUGPrednisone

5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)

Sponsors

Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI 17.5 to 30.5 kg/m2 and total body weight \>50 kg

Exclusion criteria

* Fasting glucose above the limits of the reference range for healthy individuals * No treatment OGTT indicative of impaired fasting glucose or impaired glucose tolerance * Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation

Design outcomes

Primary

MeasureTime frame
Fold change in AUC (0-4hr) relative to no treatment baseline for plasma glucose, plasma insulin and plasma C-peptide4 hours

Secondary

MeasureTime frame
Pharmacodynamic effects on plasma glucose, plasma insulin, and plasma C-peptide3 days
Safety: adverse events, vital sign measurements, physical examination3 days
Pharmacokinetics: sparse PF-04308515 plasma samples will be collected3 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026